NEUROPHET Inc.
Financials
Valuation Metrics
NEUROPHET Inc.'s Market Cap is ₩703B. Ranked #1469 of 2,410 in KR market (top 61%), #839 of 1,631 on KOSDAQ (top 51%), #53 of 94 in Health Care Equipment & Services (top 56%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 70.27B KRW | KR#1,469/2,410 Sec#53/94 |
| Revenue | 2.62B KRW | KR#2,366/2,410 Sec#94/94 |
| Net Income | -22.39B KRW | KR—/2,410 Sec—/94 |
| Total Assets | 26.88B KRW | KR#2,348/2,410 Sec#89/94 |
| Net Assets | 19.45B KRW | KR#2,290/2,410 Sec#88/94 |
| Value | ||
| P/B | 3.61x | KR#2,188/2,410 Sec#82/94 |
| P/S | 26.87x | KR#2,346/2,410 Sec#89/94 |
| FCF Yield | -21.82% | KR—/2,410 Sec—/94 |
| Profitability | ||
| ROE | -115.10% | KR#2,347/2,410 Sec#90/94 |
| ROA | -83.28% | KR#2,381/2,410 Sec#94/94 |
| Op. Margin | -632.84% | KR#2,362/2,410 Sec#94/94 |
| Financial Health | ||
| Debt Ratio | 38.21% | KR#747/2,410 Sec#36/94 |
| Total Debt | 4.80B KRW | KR#1,792/2,410 Sec#64/94 |
| FCF | -15.33B KRW | KR#1,822/2,410 Sec#70/94 |
| Cash | 4.10B KRW | KR#2,072/2,410 Sec#79/94 |
| Current Ratio | 3.61x | KR#435/2,410 Sec#29/94 |
| Performance | ||
| 1Y Return | -73.94% | KR#2,303/2,410 Sec#93/94 |
| 1M Return | -27.64% | KR#2,132/2,410 Sec#91/94 |
| From 52W High | -84.31% | KR#2,355/2,410 Sec#91/94 |
| 1Y MDD | -84.71% | KR#2,349/2,410 Sec#92/94 |
| Trading | ||
| Volume | 61,743 shares | KR#692/2,410 Sec#26/94 |
| Trading Value | 347.9M KRW | KR#790/2,410 Sec#24/94 |
| Foreign Own. | 6.64% | KR#670/2,410 Sec#18/94 |
| Per Share | ||
| EPS | -1,835 KRW | KR—/2,410 Sec—/94 |
| BPS | 1,595 KRW | KR#2,173/2,410 Sec#78/94 |
Company Info
Neurophit was established in 2016 as a specialized AI solution company for brain diseases and is scheduled to be listed on KOSDAQ in 2025. The company develops AI technology-based brain image analysis software and therapeutic medical devices, providing full-cycle brain disease medical solutions from diagnosis to treatment. Neurophit possesses AQUA for degenerative brain disease diagnosis support, SCALE PET for PET image analysis, and AQUA AD for Alzheimer's solutions, while continuously conducting R&D in various brain disease fields such as depression treatment and brain MRI. Neurophit is headquartered in Gangnam-gu, Seoul.